Literature DB >> 2013801

PET as a tool in the clinical evaluation of pituitary adenomas.

M Bergström1, C Muhr, P O Lundberg, B Långström.   

Abstract

Positron emission tomography (PET) was used in over 400 examinations in patients with pituitary adenoma. It was demonstrated that PET with carbon-11-methionine can give valuable complementary information in the diagnosis of this tumor due to PET's ability to adequately depict viable tumor tissue in contrast to fibrosis, cysts and necrosis. Furthermore, PET with dopamine D2 receptor ligands can characterize the degree of receptor binding and thus give information as to the prerequisites for dopamine agonist treatment. Most important is the very high sensitivity given by PET with carbon-11-methionine in the evaluation of treatment effects. It is concluded that when properly used PET can be fully justified in the clinical handling of patients with pituitary adenomas and other intracranial tumors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013801

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  22 in total

Review 1.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

2.  Pituitary metastasis of breast cancer confirmed by fluorine-18 fluorodeoxyglucose positron emission tomography: a case report.

Authors:  R Ersoy; O Topaloglu; C Aydin; A Dirikoc; B Cakir
Journal:  J Endocrinol Invest       Date:  2007-06       Impact factor: 4.256

3.  Analysis of 18F-fluorodeoxyglucose positron emission tomography findings in patients with pituitary lesions.

Authors:  Hannah Seok; Eun Young Lee; Eun Yeong Choe; Woo In Yang; Joo Young Kim; Dong Yeob Shin; Ho Jin Cho; Tae Sung Kim; Mi Jin Yun; Jong Doo Lee; Eun Jig Lee; Sung-Kil Lim; Yumie Rhee
Journal:  Korean J Intern Med       Date:  2012-12-28       Impact factor: 2.884

Review 4.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

5.  A study on the prognostic evaluation of carbon ion radiotherapy for head and neck adenocarcinoma with C-11 methionine PET.

Authors:  Mitsuhiko Hasebe; Kyosan Yoshikawa; Seiya Ohashi; Sachiko Toubaru; Koji Kawaguchi; Junichi Sato; Junetsu Mizoe; Hirohiko Tsujii
Journal:  Mol Imaging Biol       Date:  2010-10       Impact factor: 3.488

Review 6.  The use of FDG-PET to target tumors by radiotherapy.

Authors:  Guido Lammering; Dirk De Ruysscher; Angela van Baardwijk; Brigitta G Baumert; Jacques Borger; Ludy Lutgens; Piet van den Ende; Michel Ollers; Philippe Lambin
Journal:  Strahlenther Onkol       Date:  2010-08-30       Impact factor: 3.621

Review 7.  [Positron emission tomography in neuroscience. An integrative part of clinical diagnostic methods and experimental research].

Authors:  B Schaller
Journal:  Radiologe       Date:  2005-02       Impact factor: 0.635

8.  Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors.

Authors:  W Pirker; T Brücke; M Riedl; M Clodi; A Luger; S Asenbaum; I Podreka; L Deecke
Journal:  J Neural Transm Gen Sect       Date:  1994

9.  In vivo manganese MR imaging of calcium influx in spontaneous rat pituitary adenoma.

Authors:  D J Cross; J A Flexman; Y Anzai; T Sasaki; P M Treuting; K R Maravilla; S Minoshima
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-09       Impact factor: 3.825

10.  Results of continuous long-term intravenous application of octreotide via an implantable pump system in acromegaly resistant to operative and X-ray therapy.

Authors:  G Hildebrandt; J Zierski; G Csecsei; H W Mueller; H Stracke
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.